2023
A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management
Chetty A, Rafi E, Bellini N, Buchholz N, Isaacs D. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Endocrine Practice 2023, 30: 292-303. PMID: 38122931, DOI: 10.1016/j.eprac.2023.12.010.Peer-Reviewed Original ResearchConceptsWeight-related complicationsGlucose-dependent insulinotropic polypeptideReceptor agonistsIncretin therapiesGlucagon-like peptide-1Weight managementObesity managementLate-stage developmentOral GLP-1 receptor agonistSide effectsAssociated with weight regainReview clinical trial dataGLP-1 receptor agonistsDual GLP-1/GIP receptor agonistsGLP-1/GIP receptor agonistsWeeks of treatmentGastrointestinal side effectsClinical trial dataLevels of weight lossWeight reductionCombination therapyWeight regainClinical trialsTherapyPeptide-1
2016
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop G, Zhong J, Peters M, Goud A, Chen Y, Davis S, Mukherjee B, Rajagopalan S. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal Of Diabetes And Its Complications 2016, 32: 113-122. PMID: 29074120, DOI: 10.1016/j.jdiacomp.2016.08.018.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsOral anti-diabetic agentsGLP-1RABackground therapyGlycemic efficacyWeight lossGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsActive comparator armLong-acting GLP-1RAType 2 diabetes mellitusPeptidase-4 inhibitorsTreatment of type 2 diabetes mellitusIncretin-based therapiesActive comparator drugShort-acting agentsWeight loss effectsClinical trial evidenceType 2 diabetesRandomized Controlled TrialsReceptor agonistsAnti-diabetic agentsIncretin therapiesComparator armComparator therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply